38.6c New Delhi, India, Friday, October 07, 2022
Top Stories
Interviews Know The Law Book Reviews Videos
About Us Contact Us
Business

India’s Zydus Cadila Gets Approval From Mexico To Test COVID-19 Drug - ‘Desidustat’

By Prachi Misra      Jul 06, 2020      0 Comments      1,911 Views
India’s Zydus Cadila Gets Approval From Mexico To Test COVID-19 Drug - ‘Desidustat’

Zydus Cadila- a leading Indian Pharmaceutical Company on Monday, 6th July 2020 got approval from Mexicans regulatory authority Cofepris to test one of its drugs - ‘Desidustat’ in the fight against COVID’19. 

A Cadila healthcare official said in a regulatory filing, “Clinical and regulatory development of Desidustat in COVID-19 is being executed in Mexico by Avant Sante Research Centre S.A de C.V, a leading contract research organization headquartered in Monterrey, Mexico.” 

The company stated that it will conduct a study to evaluate the efficacy and safety of Desidustat tablets for the management of COVID-19 patients. “As a part of the study, 100mg tablets of Desidustat will be administered for a period of 14 days along with recommended standard care during the trial.”

Zydus Cadila Chairman Pankaj R Patel said, “At Zydus, we have been stepping up our efforts to fight the COVID-19 pandemic through therapeutic drugs, diagnostics, and vaccines. With Desidustat we will study a novel approach for the management of COVID-19.

Zydus Cadila had initiated two phase- III trials of Desidustat. Last week Zydus received approval from Indian Authorities to start human trials for testing the COVID-19 vaccine. Zydus is the second company to receive such a nod for testing the vaccine during the times of such pandemic worldwide.

Shares of Cadila Healthcare, the listed entity of the group, were trading at Rs 363.40 apiece on BSE, 0.78 percent lower than their previous close.



Tags:
Corona Updates
Share this article:



Leave a feedback about this




Related Posts
View All

TRENDING NEWS


TOP STORIES


ADVERTISEMENT


Lawstreet Advertisement

Signup for Our Newsletter

Get Exclusive access to members only content by email